Clinical Trials Logo

Clinical Trial Summary

Imatinib remains suboptimal for recurrence/metastasis and unresectable GIST response rates. With the maturity of genomics and metabolomics, people gradually realize the role of gut microbiota in tumor therapy. The gut microbiota may affect tumor treatment by regulating the tumor microenvironment or the host immune system, and some bacteria can fight tumors by activating the immune system. Growing evidence shows that the effect of tumor therapy is related to the composition of the gut microbiota of patients, and that the composition of the gut microbiota of patients sensitive to drug treatment has certain characteristics, and these characteristics may be used as biomarkers to predict the prognosis of treatment. At present, it remains unclear whether the efficacy of imatinib is related to the gut microbiota in GIST patients. Therefore, precise mining of microbial information and the development of reasonable and feasible microbial interventions are expected to optimize the treatment strategy of GIST to a large extent and provide a basis for individualized treatment of advanced GIST.


Clinical Trial Description

Taking Chinese patients with unresectable C-kit9/11-mutated GIST as the research object, the treatment effect was observed after standardized treatment with imatinib mesylate. To explore the relationship between intestinal flora and the efficacy of imatinib treatment, to find new biomarkers to predict the efficacy of imatinib, and to provide reference for individualized treatment of imatinib ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05895942
Study type Observational [Patient Registry]
Source Xijing Hospital
Contact jun j Yang, Master
Phone 135 7253 3693
Email yangjj@fmmu.edu.cn
Status Recruiting
Phase
Start date September 10, 2021
Completion date September 10, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05957367 - A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Phase 1/Phase 2
Completed NCT01770405 - Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract N/A
Active, not recruiting NCT03556384 - Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Phase 2
Completed NCT01459757 - Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib N/A
Completed NCT00979381 - Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor N/A
Completed NCT00399152 - Perifosine + Sunitinib Malate for Patients With Advanced Cancers Phase 1
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT04599660 - Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
Completed NCT05400018 - Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04825470 - Liver Transplantation for Unresectable GIST Liver Metastases N/A
Recruiting NCT00687778 - 11C-Acetate PET/CT Non-FDG-Avid Tumors N/A
Completed NCT00979329 - Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST N/A
Active, not recruiting NCT04927260 - French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients
Completed NCT03465722 - (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST Phase 3
Completed NCT03880617 - Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT01323400 - Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) Phase 2
Recruiting NCT05804331 - The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Completed NCT01874665 - A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Phase 2